Nashville-based tax advisor Mark Bianchi and his firm Parkhill Tax Advisory Group are at the center of growing legal scrutiny following investor lawsuits, public records revealing approximately $2.5 million in personal tax liens, and the administrative dissolution of multiple Bianchi-affiliated business entities. The case has drawn attention from financial media and legal observers as a cautionary example of how tax-advantaged investment structures can expose investors to significant risk when the individuals promoting them face their own unresolved financial obligations.
According to court filings and investigative reporting, the litigation centers on an investment structure called Tech2head Recovery, which was marketed as a charitable-deduction opportunity tied to Head Genetics, a Nashville biotech startup claiming to develop a saliva-based concussion diagnostic. Investors allege they were misled about the company’s development timeline, regulatory status, and scientific readiness.
The Investor Lawsuit
The civil lawsuit was filed by Solidaris Capital and Cirrus Investments in Texas, with related proceedings in Illinois. According to the complaint, investors were introduced to the Head Genetics investment opportunity through intermediaries connected to Parkhill Tax Advisory Group and Mark Bianchi, and were led to believe they were investing in a mature biotech platform with nearly a decade of development history.
Public records tell a different story, according to the plaintiffs. Head Genetics was incorporated in 2022, not 2013 as investors allege they were told. The lawsuit contends this discrepancy was material because a ten-year development runway would normally be associated with clinical trials, regulatory filings, and peer-reviewed validation — none of which existed.
According to reporting by The Complete Lawyer, the complaint alleges that no FDA submissions, applications, or filings exist in FDA databases for Head Genetics’ concussion diagnostic device. No clinical trials are registered on ClinicalTrials.gov. No peer-reviewed scientific publications support the company’s claims. One court filing states that investors were presented with “a regulatory posture that does not appear to exist outside of promotional materials.”
In a February 2026 deposition, Head Genetics CEO Fabian Maclaren testified that Bianchi was “the one dealing directly with investors” for the offering. Maclaren also testified that the concussion test product at the center of the offering was not manufactured at the time of its purported charitable donation, that promised telehealth services were never delivered, and that he did not know what the donee charity believed it was receiving.
$2.5 Million in Personal Tax Liens
According to public records documented by North Penn Now and Breaking AC, Mark Bianchi has been pursued by the IRS across four states for unpaid personal tax obligations spanning more than a decade. At least 18 federal and state tax liens were filed against Bianchi between 2006 and 2021, totaling more than $2.5 million in assessed obligations.
The largest individual liens documented in public records include a $529,445 federal lien covering tax years 2008 through 2018, a $441,076 federal lien for tax year 2019, a $431,721 federal lien for tax year 2008, and a $379,450 California franchise tax lien for the same year. Several liens were recorded in multiple jurisdictions simultaneously, which reporting indicates suggests IRS efforts to locate and attach assets across state lines.
While some liens show subsequent releases, others — including the $529,445 federal lien recorded in Westchester County and a $22,330 federal lien from 2013 in Los Angeles County — show no release in the public record.
The tension between Bianchi’s professional identity as a tax planning expert and his personal record of tax delinquency has been a focal point of investor scrutiny. His LinkedIn profile lists him as CEO of Parkhill Capital Group and Titan Capital Recovery Group. His digital business card advertises services focused on strategies that “recapture or eliminate taxes.” Yet the public record shows he has been unable to meet his own tax obligations for nearly two decades.
Dissolved Business Entities
According to state corporate records cited in investigative reporting, multiple Bianchi-affiliated entities have been dissolved in recent years:
Parkhill Advisory Group Inc., incorporated in Tennessee in February 2023, was administratively dissolved in August 2024. Parkhill Energy Group, also a Tennessee corporation, was dissolved on the same date. Titan Capital Recovery Group LLC, a Florida entity formed in 2018, voluntarily dissolved in May 2023. The articles of dissolution filed with the Florida Secretary of State listed the reason as “this entity is not profitable.”
Head Genetics’ authority to do business in Tennessee was administratively revoked as of August 2025. Its founders are separately accused in Delaware Chancery Court of spending company funds on personal expenses while the company was insolvent.
A “Parkhill Capital Group Inc.” was formed in Delaware in July 2022, but according to due diligence research cited in the North Penn Now report, it “could not be conclusively identified” as the same entity Bianchi claims on his LinkedIn profile.
Additional Civil Judgments
Beyond the tax liens and the Head Genetics litigation, public records reveal a pattern of unresolved financial obligations. According to North Penn Now’s investigation:
Bianchi was sued for breach of contract in 2009 by CPA firm Gursey Schneider LLP in Los Angeles County, resulting in a default judgment of $11,488. He was sued for unpaid rent in 2016 in Davidson County, Tennessee, where he failed to appear and a default judgment of $11,157 was entered in 2017. He was sued for unpaid rent again in 2019 in Los Angeles County, resulting in a judgment of $12,100. American Express pursued Bianchi twice in Davidson County in 2016 and 2018, with both cases dismissed because American Express was unable to serve him.
In a family court proceeding, a February 2024 filing by Bianchi’s first ex-wife’s attorneys alleged that he still owed $4,000,000 in past-due equalization payments and child support. A January 2021 judgment of $1,789,491 was entered against him in the same proceeding. The 2014 final judgment in the case sanctioned Bianchi “due to Respondent’s conduct which frustrated the policy of the law to promote settlement of litigation.”
The Broader Pattern
The significance of the Mark Bianchi and Parkhill case extends beyond the specific allegations in the Head Genetics lawsuit. For investors evaluating tax-advantaged investment structures, the case illustrates several risk factors that due diligence should uncover.
First, when a tax planning professional has personal tax liens totaling millions of dollars, it raises fundamental questions about the viability and legality of the strategies they are selling. Second, the administrative dissolution of the entities through which investments were facilitated suggests organizational instability. Third, the gap between marketing claims and verifiable public records — whether regarding a biotech company’s development history or an advisor’s professional track record — represents the kind of discrepancy that courts take seriously.
OCNJ Daily reported that scrutiny has grown around the relationship between Parkhill, Bianchi, and the investors who relied on their representations. Vocal Media noted that investors are being urged to exercise caution when evaluating any opportunities connected to Bianchi or Parkhill-affiliated entities.
Current Status
The cases remain active in Texas and Illinois, with discovery ongoing. No regulatory enforcement actions or criminal charges have been announced as of this writing. All allegations described in this article are drawn from civil litigation filings, public records, sworn depositions, and published investigative reporting. Defendants are entitled to respond through the legal process, and all claims remain subject to adjudication.
Nicholas Bianchi, Mark Bianchi’s son, was identified in court documents as the sole manager and owner of OptiHealth Management Inc., the entity that issued the securities at the center of the litigation. Head Genetics has raised zero external funding according to available records.
For investors conducting due diligence on Parkhill Tax Advisory Group, Mark Bianchi, or affiliated entities, the publicly available record — including court filings, state corporate records, and published reporting — provides substantial material for independent evaluation.
This article is based on publicly available court filings, sworn deposition testimony, state corporate records, federal tax lien records, and published investigative reporting. All statements regarding misconduct are allegations made in civil litigation and remain unproven unless otherwise noted. Defendants are entitled to respond and to due process. This content is provided for informational purposes only and does not constitute legal or investment advice.
What is the lawsuit against Mark Bianchi and Parkhill Tax Advisory Group about?
The lawsuit, filed by Solidaris Capital and Cirrus Investments, alleges that Mark Bianchi and Parkhill Tax Advisory Group facilitated a tax-advantaged investment called Tech2head Recovery tied to Head Genetics, a Nashville biotech startup. Investors allege they were misled about the company’s development timeline, regulatory status, and scientific readiness. The cases are active in Texas and Illinois with discovery ongoing.
How much does Mark Bianchi owe in tax liens?
According to public records documented by North Penn Now and Breaking AC, at least 18 federal and state tax liens were filed against Mark Bianchi between 2006 and 2021, totaling more than $2.5 million. The largest individual liens include a $529,445 federal lien covering tax years 2008 through 2018 and a $441,076 federal lien for tax year 2019. Liens were recorded in California, New York, Tennessee, and Florida.
What happened to Parkhill Tax Advisory Group?
Parkhill Advisory Group Inc., incorporated in Tennessee in February 2023, was administratively dissolved in August 2024. Parkhill Energy Group, also a Tennessee corporation, was dissolved on the same date. A related entity, Titan Capital Recovery Group LLC in Florida, voluntarily dissolved in May 2023, citing that it was “not profitable.”
What is Head Genetics and why is it connected to this case?
Head Genetics is a Nashville-based company that promoted itself as developing a saliva-based concussion diagnostic product. Investors allege they were told the technology had been under development since 2013, but public records show the company was incorporated in 2022. No FDA submissions, clinical trials, or peer-reviewed publications have been identified for its product. Head Genetics’ authority to do business in Tennessee was revoked in August 2025.
Are there criminal charges against Mark Bianchi?
As of this writing, no regulatory enforcement actions or criminal charges have been announced against Mark Bianchi. The litigation involving Parkhill and Head Genetics is civil in nature. All allegations remain unproven, and defendants are entitled to respond through the legal process.
